The text starts here.
Understanding Eisai

Which Therapeutic Areas is Eisai Focusing on?: Eisai concentrates its research and development resources in focus areas: neurology and oncology.

Concentrating on Focus Areas
By focusing its resources in particular areas, Eisai can stay abreast of the latest developments in treatment ranging from basic research to clinical studies as well as applicable cutting-edge techniques and healthcare trends. Based on this wealth of specialized information, Eisai can raise the success rate of its R&D endeavors and generate a steady stream of results.
Eisai has positioned neurology and oncology as its focus areas, where many diseases for which adequate treatments have yet to be established. Eisai is committed to creating new, highly effective drugs particularly in these fields by focusing R&D resources.

Contributing to Patients in Neurology Area

In neurology area, Eisai developed and markets Aricept® for the treatment of Alzheimer's disease. Eisai has continued the research since the launch of Aricept® with the aim for expanding additional indications for more patients to contribute and crating new formulations that patients can easily take.

In epilepsy area, Eisai markets Fycompa®, an in-house developed AMPA receptor antagonist with a novel mechanism of action, in Europe, the U.S. and Asia, and also commenced marketing Fycompa® in Japan in May 2016. Eisai has also launched Inovelon®/Banzel® (generic name: rufinamide) in Europe, U.S., Japan and Asia, and Zebinix® (generic name: eslicarbazepine) in Europe.

Multiple Approaches to Cancer Treatment

Eisai began research on the development of cancer treatments in 1986. Through this research, Eisai has since launched the novel microtubule dynamics inhibitor today Halaven® (generic name: eribulin) in the United States, Europe and Asia including Japan for the treatment of breast cancer. In 2015, Eisai launched the multikinase inhibitor Lenvima® (generic name: lenvatinib) in the U.S., Europe and Japan. Currently, Lenvima® has been approved for use in the treatment of thyroid cancer, and renal cell carcinoma. Eisai is advancing clinical research to verify the efficacy of Lenvima® in various other types of cancer.

What are the Other Aspects of Eisai?
What are Eisai's Strengths and Characteristics?

For more detailed information:
View detailed information Check Eisai glossaryList

Research & Development (Product Creation Systems)
Click here for expressions associated with this page
Aricept®Open a separeate window
Fycompa®Open a separeate window
Halaven®Open a separeate window
Inovelon®/BANZEL®Open a separeate window
Lenvima®Open a separeate window
Lunesta®Open a separeate window
Zebinix®Open a separeate window

   Understanding Eisai

Related Links